Abstract

Aims/hypothesisUpon tissue injury, peripheral sensory neurons release nociceptive factors (e.g. substance P [SP]), which exert local and systemic actions including the recruitment of bone marrow (BM)-derived haematopoietic stem and progenitor cells (HSPCs) endowed with paracrine pro-angiogenic properties. We herein explore whether diabetic neuropathy interferes with these phenomena.MethodsWe first investigated the presence of sensory neuropathy in the BM of patients with type 2 diabetes by immunohistochemistry and morphometry analyses of nerve size and density and assessment of SP release by ELISA. We next analysed the association of sensory neuropathy with altered HSPC release under ischaemia or following direct stimulation with granulocyte colony-stimulating factor (G-CSF). BM and circulating HSPCs expressing the neurokinin 1 receptor (NK1R), which is the main SP receptor, were measured by flow cytometry. We finally assessed whether an altered modulation of SP secretion interferes with the mobilisation and homing of NK1R-HSPCs in a mouse model of type 2 diabetes after limb ischaemia (LI).ResultsNociceptive fibres were reduced in the BM of patients and mice with type 2 diabetes. Patients with neuropathy showed a remarkable reduction in NK1R-HSPC mobilisation under ischaemia or upon G-CSF stimulation. Following LI, diabetic mice manifested an altered SP gradient between BM, peripheral blood and limb muscles, accompanied by a depressed recruitment of NK1R-HSPCs to the ischaemic site.Conclusions/interpretationSensory neuropathy translates into defective liberation and homing of reparative HSPCs. Nociceptors may represent a new target for treatment of diabetic complications.Electronic supplementary materialThe online version of this article (doi:10.1007/s00125-015-3735-0) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

Highlights

  • Diabetic patients manifest a defective release of haematopoietic stem and progenitor cells (HSPCs) following tissue injury, ischaemia or stimulation by granulocyte colony-stimulating factor (G-CSF), a condition referred to as diabetic stem cell mobilopathy [1]

  • Non-diabetic (n=6); white bars, type 2 diabetes mellitus (T2DM)-U (n=3); light grey bars, T2DM-N (n=5); dark grey, T2DM-NI (n=10). (e–g) Bar graphs showing the abundance of CD34+ (e) and NK1 receptor (NK1R)+ cells on total CD34+ cells (f) (p=0.06, non-diabetic vs T2DM-NI) in the peripheral blood (PB) of non-diabetic individuals and patients with type 2 diabetes, assessed by flow cytometry; the NK1R mean fluorescence intensity on CD34+ cells is shown in (g). (h) Dot plots of gating strategy. *p

  • To confirm the presence of a specific form of mobilopathy affecting the subpopulation of CD34+NK1R+ HSPCs, we investigated an independent cohort of 24 non-diabetic individuals and 74 patients with type 2 diabetes (ESM Table 3 and electronic supplementary material (ESM) Fig. 2)

Read more

Summary

Introduction

Diabetic patients manifest a defective release of haematopoietic stem and progenitor cells (HSPCs) following tissue injury, ischaemia or stimulation by granulocyte colony-stimulating factor (G-CSF), a condition referred to as diabetic stem cell mobilopathy [1]. This feature is emerging as a clinically relevant pathology associated with increased risk of vascular complications [1, 2]. The crucial contribution of this mechanism to post-ischaemic recovery is highlighted by the observation that BM reconstitution with Nk1r-knockout ( known as Tacr1-knockout) HSPCs results in depressed HSPC mobilisation, delayed blood-flow recovery and reduced neovascularisation after ischaemia. Patients with acute myocardial infarction show high circulating and cardiac levels of SP and NK1R-HSPCs whereas these phenomena are abrogated in infarcted patients with a denervated transplanted heart [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call